Hemab Therapeutics Holdings, Inc.

Research Hemab Therapeutics Holdings, Inc. (COAG) on Bullrun: market cap USD 1.72B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCOAG
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.72B
• Financial periodQ1 2026
• Net income-USD 22.69M
• Free cash flow-USD 21.70M

Valuation Snapshot

latest market cap is USD 1.72B.

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency;

Frequently asked questions

What is Hemab Therapeutics Holdings, Inc.'s market cap?

Hemab Therapeutics Holdings, Inc.'s market capitalization is USD 1.72B.

What does Hemab Therapeutics Holdings, Inc. do?

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.